Dragonfly and AbbVie expand their existing
collaboration in oncology and autoimmune disease to develop
additional drug candidates in immune-mediated diseases using
Dragonfly's proprietary Tri-specific NK cell Engager Therapy
(TriNKET™) platform
WALTHAM,
Mass., April 20, 2022 /PRNewswire/
-- Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology
company developing novel immunotherapies that harness the innate
immune system to treat disease, today announced an expansion of its
research collaboration with AbbVie (NYSE: ABBV) to discover and
develop Dragonfly's novel immunotherapies for new targets in
autoimmune and fibrotic diseases. AbbVie successfully licensed its
first TriNKET™ drug candidate from Dragonfly, part of a
multi-target collaboration initiated in November 2019, in January
2021.
"AbbVie is committed to delivering transformative treatment
options for patients suffering from autoimmune and fibrotic
diseases," said Dr. Jonathon
Sedgwick, Vice President and Global Head of Discovery
Research at AbbVie. "We have seen strong progress in our current
collaboration with Dragonfly focused on their triNKET technology
and are pleased to expand our partnership to include additional
immunology targets of interest to AbbVie."
"AbbVie is a global leader in treating immune-mediated diseases,
and they continue to be a terrific partner" said Bill Haney, co-founder and chief executive
officer of Dragonfly, "we look forward to building on our
successful collaboration, and rapidly progressing with the AbbVie
team to advance new treatment options for patients."
Under the agreement, Dragonfly will grant AbbVie the option to
license exclusive worldwide intellectual property rights to
multiple new candidates developed using Dragonfly's TriNKET™
technology platform. AbbVie will pay Dragonfly an upfront payment,
future success-based milestone payments and royalties.
About Dragonfly
Dragonfly Therapeutics, Inc. is
a clinical-stage biopharmaceutical company committed to
discovering, developing and commercializing therapies that use its
novel TriNKET™ technology to harness the body's innate immune
system to bring breakthrough treatments to patients.
For more information visit:
www.dragonflytx.com
https://www.linkedin.com/company/dragonfly-therapeutics-inc
https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT:
Anne Deconinck |
anne@dragonflytx.com
Related Links
http://www.dragonflytx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-multi-target-expansion-of-its-research-collaboration-with-abbvie-to-develop-novel-therapeutic-candidates-for-immune-mediated-diseases-301528850.html
SOURCE Dragonfly Therapeutics, Inc.